

**TABLE 85: TREATMENT-EXPERIENCED**

INCLUDED STUDIES	ITT N	TREATMENT GROUPS	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)						PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)		
					PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6		CIRRHOTIC	NON-CIRRHOTIC
<b>Included in the NMA for all SVR</b>																						
Afdhal et al., 2014 ION-2	109	SOF12 + LDV12	56 (6.9)/57 (24 to 67)	68	39	61	0		55	45	0		79	21						20	80	6.5 (0.44)
	111	SOF12 + LDV12 + RBV12	57 (8.0)/59 (27 to 75)	64	42	58	0		59	41	0		79	21						20	80	6.4 (0.54)
	109	SOF24 + LDV24	56 (8.3)/58 (25 to 68)	68	54	46	0		55	45	0		78	22						20	80	6.4 (0.57)
	111	SOF24 + LDV24 + RBV24	55 (7.8)/56 (28 to 70)	61	54	46	0		54	46	0		79	21						20	80	6.5 (0.60)
Andreone et al., 2014 PEARL-II	91	PAR/RIT12 + OMB12 + DAS12	54.2 (10.5)/NR (NR)	60	100	0	0		36.8	34.7	28.4			100						NA	100	6.48 (0.53)
Bourlière et al., 2015 SIRIUS	78	SOF24 + LDV24	57 (10.7)	72	100	100	0	0	100			1	64	35	0	0	0	0	0	100	0	Mean (SD): 6.5 (0.6)
	77	SOF12 + LDV12 + RBV12	56 (7.4)	75	100	100	0	0	100			1	62	36	0	0	0	0	0	98.7	1.3	Mean (SD): 6.5 (0.5)
Jensen et al., 2015 HALLMARK-QUAD	398	DCV24 + ASU24 + PR24	Median (range): 52.7 (19 to 76)	68.6	100	0	0	0	0	67	33	0	44	45	0	0	11	0	0	23.4	76.6	Mean (SD): 6.50 (0.528) for genotype 1 and 6.08 (0.549) for genotype 4
Lawitz et al., 2014	47	SOF12 + PR12	56 (range 39 to 72)	68	100	0	0	0	--	--	--	0	0	0	49	51	0	0	0	55	45	6.2 (0.7)

INCLUDED STUDIES	ITT N	TREATMENT GROUPS	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)							PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)	
					PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	CIRRHOTIC		NON-CIRRHOTIC
Lok et al., 2014 DUAL A2	20	DCV24 + ASU24	NR (NR)/ 54 (NR)	65	100	0	0		0	100	0		0	100						-	100	6.6 (0.5)
Lok et al., 2014 QUAD B2	21	DCV24 + ASU24 + PR24	NR (NR)/ 50 (NR)	57	100	0	0		0	100	0		90	10						-	100	6.5 (0.6)
Osinusi et al., 2014 SYNERGY	14	SOF12 + LDV12	NR (NR)/59 (48 to 70)	93	0	Other: DAA + R (100)	0		100	0	0		57	43						--	--	Median (range): 6.31 (5.50 to 6.76)
Pol et al., 2015	80	SOF12 + PR12	55 (10.9)	75	--	99 (79/80)	--	1 (1/80)	--	--	--	100	85	15	0	0	0	0	0	-	100	6.6 (0.5)
Reddy et al., 2015 ATTAIN	379	SIM12 PR48	Median (range): 50 (18 to 69)	64	100	0	0	0	0	62	38	0	43	57	0	0	0	0	0	23	77	Median (range): 6.56 (4.5 to 7.7)
	384	T12 PR48 q8	Median (range): 52 (20 to 69)	58	100	0	0	0	0	62	38	< 1	42	57	0	0	0	0	0	20	80	Median (range): 6.57 (4.5 to 7.6)
Wyles et al., 2015	51	SOF12 + LDV12 + RBV12	54 (8.7)	61	10	49	2	39		--		98	59	39	0	2	0	0	0	27	73	6.2 (range: 4.4 to 7.3)
Zeuzem et al., 2014 SAPPHERE-II	297	PAR/ RIT12 + OMB12 + DAS12 + RBV12	51.7 (NR)/NR (19.0 to 71.0)	56	100	0	0		29	49.2	21.9		58	41						-	100	Mean: 6.55 (range: 4.61 to 7.70)
Forns et al., 2015 C-SALVAGE	79	GRZ12 + ELB12 + RBV12	Mean 54.4	58	0	100	0	0	33		51	100	38	62	0	0	0	0	0	43	57	6.1 (0.5)

ASU = asunaprevir; BEC = beclabuvir; DAA = direct-acting antiviral; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; ITT = intention-to-treat; LDV = ledipasvir; NMA = network meta-analysis; NR = not reported; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SD = standard deviation; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response.

**NOTE: PLEASE REFER TO TREATMENT REGIMEN NOMENCLATURE TABLE FOR DESCRIPTION OF DOSAGES.**